Previous close | 6.40 |
Open | 6.40 |
Bid | 0.00 |
Ask | 5.00 |
Strike | 90.00 |
Expiry date | 2024-06-21 |
Day's range | 6.40 - 6.40 |
Contract range | N/A |
Volume | |
Open interest | 5 |
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share. The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path forwardAdditional data from the ongoing Phase 1b trial of DISC-0974 in myelofibrosis (MF) patients continued to demonstrate greater than 60% hematologic response rates, with durable increases in hemoglobin levels and reductions in transfusion burdenPositive data from initial single-ascending dose (
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 6th at 1:00 pm ET. A live webcast of the presentation will be available through the investor